Genome-wide Association Study of Traumatic Brain Injury in U.S. Military Veterans Enrolled in the VA Million Veteran Program

Victoria C. Merritt^{1,2,3,*}, Adam X. Maihofer^{1,2}, Marianna Gasperi^{1,2,3}, Elizabeth Ketema^{1,2},
Catherine Chanfreau-Coffinier⁴, Murray B. Stein^{1,2,5}, Matthew S. Panizzon^{1,2,6}, Richard
L. Hauger^{1,2,3,6}, Mark W. Logue^{7,8,9,10}, Lisa Delano-Wood^{1,3,2}, & Caroline M.
Nievergelt^{1,2,3};

- 13 on behalf of the VA Million Veteran Program
- 14 15

¹VA San Diego Healthcare System (VASDHS), San Diego, CA, United States. 16 ²Department of Psychiatry, University of California San Diego, La Jolla, CA, United 17 18 States. ³Center of Excellence for Stress and Mental Health, VASDHS, San Diego, CA, 19 United States. ⁴VA Informatics and Computing Infrastructure (VINCI), VA Salt Lake City Health Care System, Salt Lake City, UT, United States. School of Public Health, 20 University of California San Diego, La Jolla, CA, United States. ⁶Center for Behavior 21 Genetics of Aging, University of California, San Diego, La Jolla, CA, United States. 22 ⁷National Center for PTSD, Behavioral Sciences Division, VA Boston Healthcare 23 System, Boston, MA, United States. ⁸Boston University School of Medicine, Department 24 of Psychiatry, Boston, MA, United States. ⁹Boston University School of Medicine, 25 Biomedical Genetics, Boston, MA, United States. ¹⁰Boston University School of Public 26 27 Health, Department of Biostatistics, Boston, MA, United States.

- 28
- 29
- 30 *Address correspondence to:
- 31 Victoria C. Merritt, Ph.D.
- 32 VA San Diego Healthcare System (151B)
- 33 3350 La Jolla Village Drive
- 34 San Diego, CA 92161
- 35 Phone: (858) 552-8585 (x2670)
- 36 Email: <u>victoria.merritt@va.gov</u>
- 37

Abstract

38 39

40 Large-scale genetic studies of traumatic brain injury (TBI) are lacking; thus, our 41 understanding of the influence of genetic factors on TBI risk and recovery is incomplete. 42 This study aimed to conduct a genome-wide association study (GWAS) of TBI in VA 43 Million Veteran Program enrollees. Participants included a multi-ancestry cohort 44 (European, African, and Hispanic ancestries; N=304,485; 111,494 TBI cases, 192,991 45 controls). TBI was assessed using MVP survey data and ICD codes from the Veterans Health Administration's electronic health record. GWAS was performed using logistic 46 47 regression in PLINK, and meta-analyzed in METAL. FUMA was used for post-GWAS analysis. Genomic structural equation modeling (gSEM) was conducted to investigate 48 49 underlying genetic associations with TBI, and bivariate MiXeR was used to estimate 50 phenotype specific and shared polygenicity. SNP-based heritability was 0.060 (SE=0.004, p=7.83x10⁻⁶⁶). GWAS analysis identified 15 genome-wide significant (GWS) 51 loci at $p < 5x10^{-8}$. Gene-based analyses revealed 14 gene-wide significant genes, 52 53 including NCAM1, APOE, FTO, and FOXP2. Gene tissue expression analysis identified 54 the brain as significantly enriched, particularly in the frontal cortex, anterior cingulate 55 cortex, and nucleus accumbens. Genetic correlations with TBI were significant for risktaking behaviors and psychiatric disorders, but generally not significant for the 56 57 neurocognitive variables investigated. gSEM analysis revealed stronger associations 58 with risk-taking traits than with psychiatric traits. Finally, the genetic architecture of TBI 59 was similar to polygenic psychiatric disorders. Neurodegenerative disorders including 60 Alzheimer's and Parkinson's disease showed much less polygenicity, however, the proportion of shared variance with TBI was high. This first well-powered GWAS of TBI 61 62 identified 15 loci including genes relevant to TBI biology, and showed that TBI is a 63 heritable trait with comparable genetic architecture and high genetic correlation with psychiatric traits. Our findings set the stage for future TBI GWASs that focus on injury 64 65 severity and diversity and chronicity of symptom sequelae. 66

67

68

69 Introduction

70 Military personnel serving in Iraq and Afghanistan have sustained traumatic brain 71 injuries (TBIs) at a higher frequency than prior conflicts¹, prompting widespread interest 72 in the assessment and management of TBI and its associated sequelae. Within military 73 populations, the overwhelming majority of TBIs are considered "closed" head injuries; 74 among these, approximately 80% are classified as mild in severity². Although 75 designated as "mild," it has become well established that a host of clinically meaningful 76 sequelae (i.e., neurobehavioral symptoms, psychiatric distress, and problems with thinking and cognition) develop acutely post-injury³⁻⁵. Despite the expectation of full 77 recovery within days to weeks following mild TBI (mTBI)⁶, these difficulties can persist 78 for many years for some individuals⁷⁻¹⁰. Moreover, long-term outcome studies, even in 79 80 mTBI, have demonstrated an association between TBI and increased risk of dementia, 81 including Alzheimer's disease (AD), as well as chronic symptoms of posttraumatic stress disorder (PTSD) and depression^{8,11}. 82

83 Accumulating evidence also suggests that Veterans with a history of TBIespecially when combined with psychiatric comorbidities-experience poor health-84 related quality of life¹²⁻¹⁴, increased difficulties with psychosocial functioning¹⁵, and 85 greater global disability¹⁶. The costs associated with TBI assessment and management 86 87 are also substantial, with one study estimating that the median annual healthcare cost 88 per patient was approximately four times higher for Veterans with a history of TBI compared to Veterans without a history of TBI17. It is thus crucial to deepen our 89 90 understanding of the risk factors associated with sustaining a TBI as well as the 91 underlying factors that contribute to poor outcome and recovery following TBI.

92 It has been hypothesized that there are several mechanisms by which genetics 93 may influence risk for and response to neurotrauma, including pre-injury risk factors for 94 sustaining a TBI (e.g., risk-taking behaviors, impulsivity, substance use); the acute 95 response to neurotrauma (i.e., extent of injury); the repair or recovery processes 96 following injury (i.e., capacity for recovery); and pre- and post-injury cognitive capacity and cognitive reserve¹⁸. However, large-scale genetic studies of TBI are lacking and 97 98 thus our understanding of the influence of genetic factors on TBI risk and recovery 99 remains incomplete. Examining the role of genetics in TBI risk and recovery may offer novel mechanistic insights and lead to important discoveries that can inform preventive 100 101 efforts and innovative treatments for affected individuals.

102 Among the published studies that have examined genetic associations with TBI 103 risk and recovery, findings are considerably disparate, likely due to varied 104 methodologies as well as inadequate sample sizes and therefore low power to detect meaningful differences in TBI samples¹⁸⁻²³. Furthermore, existing studies have largely 105 adopted a "candidate gene" approach, focusing on a specific gene of interest-most 106 commonly, the apolipoprotein E (APOE) gene²⁴⁻²⁸, though it is widely believed that 107 108 genetic predisposition to complex traits or conditions is highly polygenic. Thus, not only 109 are adequately powered studies needed to better understand the influence of genetic 110 markers on TBI risk and recovery but, given the likelihood that multiple genes may be 111 involved, critical next steps are to apply the concept of polygenic risk to TBI and 112 capitalize on recent advances in genetics and genomics research-namely, the 113 implementation of genome-wide association studies.

114 Until recently, it had been very challenging to amass a sufficient number of cases 115 to adequately carry out a genome-wide association study (GWAS) in TBI. However, the 116 VA Million Veteran Program, a nationwide research initiative that examines how genes influence health and behaviors²⁹, affords a unique opportunity to explore a large cohort 117 of U.S. military Veterans with and without a history of TBI. In this GWAS of TBI using 118 119 Veterans Health Administration's (VHA) electronic health record data, we assessed TBI 120 history among military Veterans. We examined genome-wide significant (GWS) variants 121 associated with TBI in a multi-ancestry sample, and separately examined Veterans of 122 European ancestry (EA), African ancestry (AA), and Hispanic ancestry (HA). We 123 examined replication of results with data from another biobank, FinnGen (which 124 included individuals of EA only), and assessed SNP-based heritability. We then 125 examined genetic correlations with various health domains, including risk-taking 126 behaviors, psychiatric disorders, neurocognition, and brain morphometrics, and 127 evaluated phenotype-specific and shared polygenicity among these traits.

128

129 Methods

130

131 Procedures

132 This research was conducted as part of project "MVP026" within the Million 133 Veteran Program (MVP). The MVP, sponsored by the Department of Veterans Affairs 134 Office of Research and Development, is a nationwide initiative offering military Veterans 135 the opportunity to participate in research that seeks to better understand how genetic 136 factors influence health. Upon consenting to participate in MVP, participants are asked 137 to complete two comprehensive surveys-the "Baseline Survey" and "Lifestyle 138 Survey"—and provide a blood sample for genetic analysis. Participants also consent to 139 provide MVP investigators access to their VHA electronic health record (EHR). MVP study procedures have been previously described by Gaziano and colleagues²⁹. The 140 141 overarching MVP project was approved by the VA Central Institutional Review Board 142 (IRB) in 2010 and this specific project ("MVP026") received VA Central IRB approval in 143 2019.

143 **Z**

145 Participants

Veterans (N=304,485; 111,494 TBI cases; 192,991 controls) were included in this study if they had both phenotype and genotyping data available (described below in more detail). The EA cohort included 249,785 Veterans (85,613 cases; 164,172 controls); the AA cohort included 35,470 Veterans (15,714 cases; 19,756 controls); and the HA cohort included 19,230 Veterans (10,167 cases; 9,063 controls). See Table 1 for overall (multi-ancestry) sample characteristics and Supplemental Table 1 for EA, AA, and HA sample characteristics.

- 153
- 154 MVP Data Sources

155 The following data sources (from MVP v20_1 data release) were used to gather 156 information pertaining to TBI history: MVP Baseline Survey, MVP Lifestyle Survey, and 157 *International Classification of Diseases, 9th Revision Clinical Modification* (ICD-9) and 158 *International Classification of Diseases, 10th Revision Clinical Modification* (ICD-10) 159 codes gleaned from Veterans' EHRs.

MVP Baseline Survey: The MVP Baseline Survey gathers information pertaining 160 to sociodemographics, military history, health status and habits, and medical history and 161 162 health care usage. Within the "Medical History and Health Care Usage" section of the 163 survey, Veterans are provided a list of health conditions and are asked to self-report whether they have been diagnosed with any of the health conditions. Two guestions 164 165 pertaining to TBI were extracted from the MVP Baseline Survey and utilized in our TBI 166 phenotype: "Concussion or loss of consciousness" and "Traumatic brain injury" 167 (hereafter labeled "BL-CC" and "BL-TBI," respectively).

168 MVP Lifestyle Survey: The MVP Lifestyle Survey gathers information pertaining 169 to psychosocial health and activities, men's and women's health, exercise and nutrition, 170 well-being, and military and environmental experiences. Within the "Military and 171 Environmental Experiences" section of the survey, Veterans are asked specifically 172 about deployment-related experiences. If a Veteran indicates that they have been 173 deployed and served in a combat or war zone, they are asked additional questions to 174 assess for history of deployment-related TBI. These questions, based on the Brief Traumatic Brain Injury Screen³⁰, were designed to assess mechanism of injury, signs or 175 176 symptoms associated with TBI, and current symptoms. Specific questions were as follows: (1) "Did you have any injury(ies) during your deployment from any of the 177 following?", with response options including "fragment," "bullet," "vehicular," "fall," 178 179 "blast," "other," and "none"; (2) "Did any injury received while you were deployed result 180 in any of the following?", with response options including "being dazed, confused or 181 seeing stars," "not remembering the injury," "losing consciousness [knocked out] for less than a minute," "losing consciousness for 1-20 minutes," "losing consciousness for 182 longer than 20 minutes," "having any symptoms of concussion afterward (such as 183 184 headache, dizziness, irritability, etc.)," "head injury," and "none of the above"; and (3) 185 "Are you currently experiencing any of the following problems that you think might be related to a possible head injury or concussion?", with response options including 186 "headache," "dizziness," "memory problems," "balance problems," "ringing in the ears," 187 "irritability," "sleep problems," and "other". Responses to the second question pertaining 188 189 to signs and symptoms associated with TBI (hereafter labeled "LS-Q39") were extracted 190 from the MVP Lifestyle Survey and utilized in our TBI phenotype.

191 <u>ICD-9/ICD-10 Codes</u>: ICD-9/10 codes pertaining to TBI were extracted from the 192 EHR. TBI-specific ICD-9/10 codes were established using surveillance case definitions 193 for TBI set forth by the Armed Forces Health Surveillance Branch of the Military Health 194 System.³¹ The list of ICD-9 and ICD-10 codes utilized in this study is provided in 195 Supplemental Tables 2 and 3, respectively.

196197 TBI Phenotyping

198 <u>TBI Case Definition</u>: To be considered a TBI case, there must have been 199 evidence of TBI as determined by: (1) endorsement of BL-CC *or* (2) endorsement of BL-200 TBI *or* (3) endorsement of at least one sign/symptom associated with TBI on LS-Q39 *or* 201 (4) at least one inpatient or outpatient ICD-9/10 code for TBI. In other words, Veterans 202 with evidence of *any one or more* of these criteria were classified as a TBI case.

203 <u>TBI Control Definition</u>: To be considered a TBI control, there must have been no 204 evidence of TBI as determined by: (1) no endorsement of BL-CC *and* (2) no 205 endorsement of BL-TBI *and* (3) no endorsement of any signs/symptoms associated with

TBI on LS-Q39 *and* (4) at least one inpatient or outpatient ICD-9/10 diagnosis in the EHR but no ICD-9/10 codes for TBI at any point in the EHR. In other words, Veterans must have completed the MVP Baseline Survey and MVP Lifestyle Survey and not reported any event consistent with TBI on either survey. Additionally, there must have been evidence of VHA usage as determined by the presence of an inpatient or outpatient ICD-9/10 diagnosis, but no TBI ICD codes in the EHR.

212

213 MVP Genotyping Procedures

The MVP Bioinformatics Core completed the data cleaning and processing for all genetics data. All genetic analyses for this study utilized MVP Release 4 data. MVP genotyping procedures have been described in detail elsewhere²⁹; briefly, the "Affymetrix Axiom Biobank Array" was used for genotyping and standard quality control procedures were applied. Phasing occurred using Eagle v2.4 and imputation occurred through Minimac v4 using the Haplotype Reference Consortium panel^{32,33}.

220

221 Ancestry Assignment & Principal Components

For this study, the harmonized ancestry and race/ethnicity (HARE) method³⁴ was used to inform genetic ancestry for GWAS; ancestry groups included EA, AA, and HA. KING³⁵ was used to estimate relatedness (defined as kinship coefficient > 0.0884); related individuals were removed from analysis by prioritizing cases and removing controls. When related pairs were both cases (or both controls), one individual was removed at random. FlashPCA2³⁶ was used to compute principal components (PCs) within each ancestry group.

229

230 GWAS and Meta-Analysis

Separate GWASs were conducted for each ancestry group (EA, AA, and HA). 231 232 Logistic regression analyses were performed to evaluate associations between genotype dosage data and TBI case-control status using PLINK³⁷, including the first 10 233 234 PCs as covariates. The standard genome-wide significance threshold was used (p < 5 x235 10^{-8}). SNPs with MAF < 1% or an imputation information score < 0.6 were excluded from the results. Multi-ancestry meta-analysis was conducted in METAL³⁸ using SNPs 236 237 present in all datasets. To produce regional visualizations of GWS loci, LocusZoom 1.4³⁹ was used. The 1000 Genomes phase 3 reference data (1KGPp3)³² was utilized to 238 239 calculate LD, relying on ancestry-specific reference genotypes.

240 241 **5**

241 Replication

GWS SNPs in the EA MVP cohort were compared to the largest available external TBI data repository—FinnGen (<u>https://www.finngen.fi/en</u>). Within FinnGen (Release 7), two TBI phenotypes were examined, one for "concussion" (15,787 cases, 184,565 controls) and one for "severe TBI" (4,927 cases, 304,227 controls).

246

247 Functional Mapping and Annotation

Functional Mapping and Annotation (FUMA) software⁴⁰ was used for functional mapping and annotation of GWAS results (default settings were used unless otherwise specified), with annotations derived from human genome assembly GRCh37 (hg19). To delineate independent genomic risk loci (defined by $r^2 > 0.6$) and variants in LD with

lead SNPs, the SNP2Gene module was applied using ancestry-appropriate reference
genotypes. To map risk loci to protein-coding genes, a 10kb window size was used.
eQTL mapping was completed for significant SNP-gene pairs (FDR < 0.05) using GTEx
v8 brain tissue expression data.

256

257 Gene-Based Results and Gene-Pathway and Tissue-Enrichment Analyses with 258 MAGMA

Multi-Marker Analysis of GenoMic Annotation (MAGMA⁴¹) was used to conduct 259 analyses pertaining to genes and tissue enrichment (i.e., gene-based, gene-pathway, 260 261 and tissue-enrichment analyses). Regarding gene-based analyses, SNPs were mapped 262 to 18,873 protein coding genes, and Bonferroni correction was used to establish the 263 GWS threshold for these analyses ($p=0.05/18,873=2.65\times10^{-6}$). To determine whether 264 specific biological pathways were associated with TBI, 15,485 curated gene sets and 265 GO terms (from MsigDB) were used in a pathway analysis; Bonferroni correction was again applied ($p=0.05/15,485=3.23\times10^{-6}$). Finally, tissue-enrichment analyses were 266 267 carried out using GTEx v8 RNA-seq and BrainSpan RNA-seq expression data.

268

269 SNP-Based Heritability Estimation and Genetic Correlations

SNP-based heritability (SNP- h^2) was computed using linkage disequilibrium score regression (LDSC)⁴² in the EA cohort. The 1KGPp3 EA reference sample was used to calculate input LD scores. Both observed scale and liability scale SNP- h^2 are reported; liability scale SNP- h^2 was computed using a population prevalence of 2% and 20%. Genetic correlations (r_g) were also computed using LDSC.

275

276 Univariate and Bivariate Gaussian Mixer Model (MiXeR) Analysis

MiXeR v1.3⁴³ was used to estimate polygenicity and discoverability of causal variants for TBI. Polygenicity estimates reflect the number of loci needed to explain 90% of SNP- h^2 . Bivariate MiXeR⁴⁴ was utilized to estimate phenotype specific and shared polygenicity. Akaike information criteria (AIC) values were used to evaluate model fit.

281

282 Genomic Structural Equation Modeling (gSEM)

Genomic structural equation modeling (gSEM) was conducted using GWAS 283 summary statistics in R⁴⁵ (using the genomicSEM package⁴⁶). LDSC⁴² was carried out 284 285 in the EA cohort to estimate the genetic covariance matrix and the sampling covariance 286 matrix using the 1KGPp3 EA reference for the following variables: TBI, general risk 287 tolerance (GRT), major depressive disorder (MDD), attention-deficit/hyperactivity 288 disorder (ADHD), alcohol dependence (ALCH), posttraumatic stress disorder (PTSD), 289 reaction time (RT), verbal numeric reasoning (VNR), neuroticism (NEUR), Parkinson's 290 disease (PD), and Alzheimer's disease (AD). Additionally, we evaluated the following 291 brain morphometric variables: nucleus accumbens (NCA), amygdala (AM), brainstem 292 (BS), caudate nucleus (CN), globus pallidus (GP), putamen (PU), thalamus (TH), 293 hippocampal volume (HV), intracranial volume (ICV), full surface area (FSA), and full 294 average thickness (FT). SNPs within the major histocompatibility region were removed 295 in the calculation of genetic covariance.

Exploratory factor analysis (EFA) was used to assess the number of latent factors among variables pertaining to TBI, risk-taking behaviors, and psychiatric

disorders. Using the R *factanal* function, EFA was carried out on the odd chromosomes and then confirmatory factor analyses (CFAs) were carried out on the covariance matrix from the even chromosomes. A factor loading threshold of 0.35 or greater was required from the EFA for variables to be assigned to factors in the CFA. The weighted least squares estimator was used to fit the data. Model fit was evaluated using the chi-square test *p*-value, comparative fit index (CFI), AIC, and standardized root mean square residual (SRMR).

305

306 Phenome-wide Association Study (PheWAS)

A PheWAS for GWS SNPs from the TBI GWAS was conducted using GWAS Atlas (<u>https://atlas.ctglab.nl/PheWAS</u>)⁴⁷. SNP rs-ID's were entered and traits were sorted by "Domain and P-value" and the max P-value was set to 0.05. Data were downloaded from the GWAS Atlas website and plotted in R. Bonferroni correction was applied (p=0.05/3,302=1.51x10⁻⁵).

312

313 **Results**

- 314
- 315 SNP-Based Results

316 The multi-ancestry meta-analysis GWAS of TBI (case-control) was conducted 317 using a sample of 304,485 Veterans (111,494 cases; 192,991 controls). A Manhattan 318 plot of the complete results is shown in Figure 1. We identified 15 genome-wide 319 significant (GWS) independent loci (Table 2). Regional annotation plots of GWS loci are 320 presented in Supplemental Figure 1. The leading SNP of the most significant locus 321 (rs1940701, locus 13) was located in NCAM1 on chromosome 11. The leading SNP of 322 the second most significant locus (rs729053, locus 17) was in TCF4 on chromosome 18. The leading SNP of the third most significant locus (rs429358, locus 19) was in 323 324 APOE on chromosome 19. Notably, rs429358 is one of the two polymorphisms (alongside rs7412) that determines the APOE haplotype⁴⁸. 325

326 When examining Veterans of EA only (N=249,785; 85,613 cases, 164,172 327 controls), we similarly identified 15 GWS independent loci. As in the multi-ancestry 328 analysis, the most significant locus was in NCAM1, with the same leading variant (rs1940701) identified. Of the 15 loci, 4 were distinct from the multi-ancestry analysis 329 (Table 2, Supplemental Figure 2), but all had been suggestive of significance ($p < 1 \times 10^{-6}$) 330 331 in the multi-ancestry meta-analysis. The leading SNP of the most significant of these 4 332 distinct loci was in ARHGAP15 on chromosome 2 (rs34799259, locus 5). Supplemental 333 Table 4 shows functional mapping and annotation of the TBI GWAS results in the EA 334 cohort. No GWS loci were identified in Veterans of AA (N=35,470; 15,714 cases, 19,756 335 controls) or HA (N=19,230; 10,167 cases, 9,063 controls; Table 2, Supplemental 336 Figures 3-4).

- 337
- 338 Replication

We performed replication analysis of the 15 EA GWS loci in the FinnGen concussion phenotype GWAS (15,787 cases, 184,565 controls; Supplemental Table 5). rs71149745 (locus 10, *FOXP2*) remained significant after adjustment for multiple comparisons. Three additional loci were at least nominally significant (at p<.05): (1) rs1940701, nearest to *NCAM1* (locus 13); (2) rs12705715 (locus 9); and (3) rs1320139

(a proxy variant for rs34799259, locus 5), nearest to ARHGAP15. A sign test was 344 345 performed to determine whether the direction of effects corresponded across studies at 346 a rate beyond chance (50%). The direction of effects matched for 13 of the 15 variants, 347 a significantly greater rate of correspondence than chance (p=.001). When comparing 348 the MVP EA case-control TBI phenotype to the FinnGen severe TBI phenotype (4,927 349 cases, 304,227 controls; Supplemental Table 4), two of the 15 possible SNPs nominally 350 replicated at p<.05: (1) rs71149745, nearest to FOXP2 (locus 10) and (2) rs4933752 (a 351 proxy variant for rs34350548, locus 12), nearest to EXOC6.

352

353 Gene-Based Analyses

354 In the genome-wide gene-based association study in the multi-ancestry cohort, 355 14 genes were determined to be gene-wide significant following Bonferroni correction 356 for multiple comparisons (Table 3, Supplemental Table 6, Supplemental Figure 5a). The top gene identified was NCAM1 ($p=4.10 \times 10^{-12}$), which was already named in positional 357 mapping of the SNP-based analysis results, followed by APOE ($p=1.30 \times 10^{-9}$), FTO 358 $(p=6.94 \times 10^{-9})$, and FOXP2 $(p=2.68 \times 10^{-8})$, also all positionally mapped to significant loci 359 from the SNP-based analysis. In contrast, five of the significant genes from this analysis 360 (MSRA, FAM120A, NAV3, RBFOX1, and DCC) were not identified based on positional 361 362 mapping of loci from the SNP-based analysis. MSRA is located on the chromosome 8 inversion region⁴⁹ where LD patterns are such that the association may be tagging the 363 364 inversion itself rather than MSRA specifically.

We also examined GWS genes in Veterans of EA, AA, and HA separately. In the EA cohort, 18 genes were determined to be GWS following Bonferroni correction (Table 3, Supplemental Table 7, Supplemental Figure 5b). Eight of these genes (*AKAP10, BRWD3, FAM46D, FBXL17, PHF2, RCN2, TCF12,* and *TSSK1B*) were distinct from the multi-ancestry gene-based analysis. Among these, the leading association was with *PHF2.* In the AA and HA cohorts, there were no gene-wide significant genes identified (data not shown).

372

373 Gene Tissue Expression

We used FUMA software⁴⁰ to evaluate gene-tissue expression in the multi-374 375 ancestry cohort. Results showed that among 30 general tissues, the brain was the only 376 significantly enriched tissue, particularly in the frontal cortex, anterior cingulate cortex, 377 and nucleus accumbens (tissues aggregated: Figure 2a, Supplemental Table 8; 378 stratified by tissue subtype: Figure 2b, Supplemental Table 9). Additionally, gene-set 379 analyses were conducted to understand potential gene pathways of importance: however, results did not identify any significant gene sets in the multi-ancestry cohort 380 381 (Supplemental Table 10). When evaluating Veterans of EA separately, there were no 382 significant gene-tissue expression results and no significant gene sets (Supplemental 383 Tables 11-12; Supplemental Figures 6a-6b).

384

385 SNP-Based Heritability

Linkage disequilibrium score regression $(LDSC)^{42}$ was used to estimate SNPbased heritability $(SNP-h^2)$ of the case-control TBI phenotype in the EA cohort. Observed SNP- h^2 was estimated to be 0.060 (SE=0.004, p=7.83x10⁻⁶⁶). On the liability scale, at 2% population prevalence, SNP- h^2 was 0.044 (SE=0.003); at 20% population

prevalence, SNP- h^2 was 0.087 (SE=0.005). To obtain further insights into the genetic architecture of TBI, we used univariate MiXeR analysis to decompose heritability into discoverability and polygenicity (number of influential variants) subcomponents. An estimated 10,470 (SE=848) influential variants explain 90% of the SNP- h^2 and the discoverability was 9.2x10⁻⁶ (SE=6.7x10⁻⁷). The 15 variants identified in the EA GWAS explained an estimated 0.2% of the heritability of TBI.

396397 Genetic Overlap

398 We examined genetic correlations (r_a) between the MVP TBI variable and a 399 variety of a priori selected health domains including risk-taking behaviors, psychiatric 400 disorders, neurocognitive variables, and brain morphometrics in the EA cohort (Figure 401 3, Supplemental Tables 13-16, Supplemental Figures 7-8). The strongest genetic correlation was with PTSD (r_0 =0.69, SE=0.04, p=2.5x10⁻⁷⁵). Broadly, genetic 402 403 correlations with TBI were moderate-to-large for risk-taking behaviors and psychiatric 404 disorders. TBI was also negatively correlated with verbal numeric reasoning (r_{a} =-0.35, 405 SE=0.03, $p=4.2\times10^{-42}$). Genetic correlations with reaction time and neurogenerative 406 disorders (i.e., AD and PD) were not significantly different from 0 after adjustment for 407 multiple comparisons. With regard to brain morphometrics, TBI was weakly genetically 408 correlated to ICV (r_{q} =-0.12, SE=0.04, p=0.002), but all other brain morphometric 409 correlations were not significantly different from 0.

410 We used univariate and bivariate MiXeR to perform a more detailed evaluation of 411 the genetic overlap between TBI and these phenotypes. Univariate analyses suggest 412 that the genetic architecture of the TBI phenotype (i.e., the polygenicity and 413 discoverability of risk variants) was similar to polygenic psychiatric disorders 414 (Supplemental Tables 17-18). In contrast, neurodegenerative disorders such as AD 415 were characterized by relatively low polygenicity but high discoverability. In bivariate 416 analyses, for five phenotypes investigated (AD, neuroticism, risky behaviors, reaction 417 time (RT), and verbal numeric reasoning), there was evidence of polygenic overlap with 418 TBI beyond what was explained by a genetic correlation model (best vs min AIC > 0). 419 Notably, while the genetic correlations of TBI with AD and RT were not significantly 420 different from 0, MiXeR reported that 60% (number of shared influential variants=57, 421 SE=23) of the influential variation in AD and 94% (number of shared influential 422 variants=8,902, SE=502) of the influential variation in RT were shared with TBI 423 (Supplemental Figures 9-10). MiXeR also reported the existence of genetic variation 424 specific to PD (best vs max AIC = 0.57), where the r_q estimated among only shared 425 influential variants was -0.83 (SE=0.14).

426

427 Genomic Structural Equation Modeling (gSEM)

Given the strong genetic correlations between TBI and risk-taking behaviors and 428 psychiatric disorders, genomic structural equation models⁴⁶ were conducted within the 429 430 EA cohort to better understand whether TBI is more genetically associated with a latent 431 factor representing risk-taking behaviors versus a latent factor representing psychiatric 432 disorders. Pairwise genetic correlations were calculated between all phenotypes to 433 produce a genetic correlation matrix (Supplemental Figure 7-8) for use in factor 434 analysis. In genomic confirmatory factor analysis, the TBI variable loaded onto its own 435 factor while the psychiatric disorders loaded onto one factor and the risk-taking

436 behaviors loaded onto another factor (CFI=0.908) (Figure 4). The correlation between 437 the TBI and psychiatric disorders factors was 0.55 (SE=0.04), and the correlation 438 between the TBI and risk-taking behaviors factors was 0.73 (SE=0.06), indicating that 439 TBI risk has a stronger genetic correlation with risk-taking behaviors than with the 440 psychiatric disorders. When examining genetic associations between TBI and individual 441 psychiatric disorders, PTSD, alcohol dependence, and ADHD showed the strongest 442 associations with TBI (Supplemental Figure 7). Given this observation, a final set of 443 analyses was run to examine the genetic correlation between these individual disorders 444 and TBI, controlling for the genetic association with risk-taking. These multiple 445 regression models are presented in Figure 5; the model with PTSD continued to showed the strongest relationship with TBI even after accounting for risk-taking. 446

447448 *PheWAS*

449 Our PheWAS examined associations of leading variants in TBI risk loci with 450 phenotypes across 28 domains (Supplemental Figure 11, Supplemental Table 19). The 451 most common associations were with phenotypes in psychiatric (11 loci), activities (9 452 loci), metabolic (8 loci), and environment (7 loci) domains (Supplemental Figure 12). 453 Considering the degree of pleiotropy of the loci, the (median) average locus was 454 associated with phenotypes across three different domains. Loci 15 (FTO) and 19 455 (APOE) had significant associations with the largest number of domains (16 and 15 456 domains, respectively). In contrast, six loci were only associated with phenotypes within 457 a single domain (e.g., locus 7, which was only associated with a phenotype in the 458 skeletal domain [osteoarthritis]).

459 460

461 **Discussion**

Examining the role of genetics in TBI risk and recovery may offer novel 462 463 mechanistic insights and lead to important discoveries that can inform preventive efforts 464 and innovative treatments for patients who have sustained TBIs. In this study, we present the largest GWAS to date for TBI using data from the VA Million Veteran 465 Program. Our results showed GWS variants associated with a TBI case-control 466 467 phenotype in a multi-ancestry cohort of Veterans. These associations were primarily driven by the EA cohort, which comprised the majority of the overall sample (82%), and 468 469 findings replicated in the FinnGen cohort (notably, the direction of effects matched for 470 13 of the 15 variants). We also independently evaluated Veterans of African and 471 Hispanic ancestry, but found no independent GWS loci, likely owing to reduced sample size and therefore lower power in those groups. 472

473 In the multi-ancestry cohort, our SNP-based results revealed 15 GWS loci, and 474 our gene-based results revealed 14 gene-wide significant genes, many of which have 475 presumed roles in psychiatric and neurologic functioning. The top GWS SNPs within the 476 multi-ancestry sample were in and around NCAM1, followed by APOE, FTO, and 477 FOXP2. Notably, many of these genes have emerged as significant genes in prior studies of neuropsychiatric and neurodegenerative conditions. For example, NCAM1 478 479 (neural cell adhesion molecule 1) is a glycoprotein expressed on the surface of neurons, 480 glia, and skeletal muscle, and has been shown to have a role in several brain-related 481 biological processes such as neuronal development and maintenance as well as

synaptic plasticity⁵⁰⁻⁵². The *NCAM1* gene has been associated with cognitive
 functioning, particularly learning and memory, and has been implicated in a range of
 neuropsychiatric and neurodegenerative disorders including schizophrenia, mood and
 anxiety disorders, and AD⁵¹.

Another notable gene to emerge as significant was APOE. APOE is a protein 486 487 expressed in peripheral tissues and the central nervous system and its primary function 488 is facilitating the transportation and distribution of lipids throughout the body. APOE 489 plays a role in neuronal maintenance, neural transmission, neuroinflammation, and 490 synaptic plasticity within the brain and has been associated with response and repair processes following neurotrauma^{53,54}. The APOE ε4 allele is a major risk factor for AD⁵⁵⁻ 491 ⁵⁷, and other research has shown associations between APOE and medical conditions 492 such as vascular dementia, diabetes mellitus, and cardiovascular disease^{58,59}, as well 493 as with cognitive functioning⁶⁰. Furthermore, our findings of an association between 494 APOE and TBI align with previous candidate gene studies in TBI^{18,19,61-64} and may help 495 496 to explain the heterogeneous neurocognitive outcomes observed chronically following 497 TBI. However, it is important to note that our association was observed with a single 498 APOE SNP (and not the APOE haplotype which defines the APOE ε4 allele, which was 499 not examined), and the effect of the haplotype may be different. Follow-up studies by 500 our group are planned to more comprehensively address the role of the APOE 501 haplotype in the context of TBI.

502 As for FTO (Fat and Obesity-Associated), less is known about the physiological 503 function of this gene in the brain; however, FTO has been found to have important 504 actions in metabolic and cardiovascular systems and may be associated with body mass index, obesity risk, and type 2 diabetes^{65,66}. *FTO* gene variants have also been causally associated with risk of AD⁶⁷ and have been reported to promote 505 506 phosphorylation of tau by activating the mTor pathway⁶⁸, which has been implicated in 507 508 AD pathophysiology. Finally, FOXP2 (forkhead box P2) is a protein that is active in 509 several tissues including the brain, and was initially implicated in speech and language development^{69,70}. FOXP2 has also been shown to play a role in other biological 510 511 processes including brain development, cell differentiation and proliferation, and neurodegeneration^{69,70}, and has previously been implicated as a genetic variant 512 513 associated with ADHD, risk-taking behaviors, and psychiatric disorders such as PTSD^{70,71}. Taken together, these observations offer critical insights into the genes that 514 515 are associated with TBI. Although the functional significance of these genes within the 516 context of TBI will still need to be determined, these initial findings are promising and 517 offer targets for future research.

To better understand the role of TBI-associated genes in higher-order systems, 518 519 we examined gene tissue expression. As expected, our results showed that the brain 520 was the only significantly enriched region, with TBI-associated genes specifically 521 implicated in the cortex, frontal cortex, anterior cingulate cortex (ACC), nucleus 522 accumbens, caudate, hippocampus, amygdala, putamen, cerebellum, cerebellar 523 hemisphere, and hypothalamus. These findings converge with a recent GWAS 524 examining risk tolerance that similarly showed significant gene expression in brain regions such as the frontal cortex, ACC, and cortex⁷². Of note, the ACC is well-known to 525 have connections with both the limbic system and the prefrontal cortex and has been 526

527 implicated in decision-making and impulse control^{73,74}, underscoring the biological link 528 between TBI and risk-taking.

With regard to SNP-based heritability of the TBI phenotype, we found an 529 530 observed heritability of 6%, which is generally consistent with other heritability statistics reported for risk-taking behaviors (e.g., general risk tolerance: SNP- h^2 =0.05⁷²), 531 psychopathology (e.g., PTSD [MVP]: SNP- h^2 =0.05-0.07⁷¹), and neurocognition (e.g., 532 533 AD, SNP- h^2 =0.07⁷⁵). Notably, there are no adequately powered studies reporting SNP-534 h^2 for TBI for comparison. Future studies are thus needed to further explore the 535 heritability of TBI and to specifically tease apart heritability associated with TBI 536 acquisition versus TBI sequelae.

Finally, we examined genetic correlations and our LDSC results suggest that 537 538 there is significant genetic overlap between the TBI case-control phenotype and risk-539 taking behaviors and psychopathology. In contrast, there was weak genetic correlation 540 between the TBI case-control phenotype and cognition and brain morphometrics, with 541 the exception of verbal numeric reasoning. gSEM analyses further confirmed underlying 542 genetic associations between TBI and both risk-taking behaviors and psychiatric 543 disorders, though the association was stronger between TBI and risk-taking. Still, when 544 evaluating individual traits/conditions, PTSD had the strongest genetic overlap with TBI, followed by ADHD and alcohol use when controlling for general risk tolerance, providing 545 546 evidence of shared genetic etiology. Finally, MiXeR results showed that the genetic 547 architecture of TBI was similar to polygenic psychiatric disorders and risk-taking traits. 548 In contrast, neurodegenerative disorders such as AD showed much less polygenicity 549 but had a high degree of shared variance with TBI. The discrepancies between the architectures of TBI and neurodegenerative disorders suggest that results need to be 550 551 interpreted with caution; however, they are at least indicative of shared genetics.

552 This is the first large-scale GWAS of TBI in the VHA and findings significantly 553 advance understanding of the genetic basis of TBI. Nevertheless, there are caveats to 554 consider when interpreting our findings. To maximize sample size and ensure sufficient 555 power, we defined a TBI case as any positive indication of TBI on either the MVP 556 Baseline Survey or MVP Lifestyle Survey, or at least one inpatient or outpatient ICD 557 code for TBI. In theory, this approach allowed us to capture lifetime history of TBI. 558 However, the diverse methods of data collection, as well as the lack of precise 559 information on the timing between injury event and reporting or documentation of the 560 event, may have impacted results. Of note, the MVP Baseline Survey specifically 561 assessed for lifetime history of concussion/TBI whereas the MVP Lifestyle Survey 562 evaluated deployment-related TBI. Furthermore, the ICD codes were limited to the data 563 available within the Veterans' VA EHRs, which may omit historical TBIs (i.e., TBI 564 sustained prior to military service/enrollment in VA). Given the data, our TBI phenotype 565 specifically focused on whether or not Veterans had a history of TBI, though it is 566 possible that our phenotype also captured aspects of TBI recovery. Future MVP studies 567 are planned to further understand the genetics associated with TBI-associated sequelae (e.g., "post-concussive syndrome" or "persistent post-concussive symptoms") and other 568 569 aspects of TBI recovery, as it is likely that different genes may be associated with TBI 570 acquisition/susceptibility vs. TBI outcome. Moreover, given that we did not evaluate or 571 consider TBI severity in our analyses, future research may also consider evaluating TBI 572 or TBI-associated variables on a continuum—for example, examining injury severity or 573 injury characteristics such as LOC or PTA.

574 Final study caveats relate to sample characteristics. Notably, the MVP cohort is 575 predominately male; given our findings and the strong associations observed with risk-576 taking behaviors and psychiatric traits, it will be important for future research to 577 determine whether genetic associations differ as a function of biological sex. The MVP 578 cohort may be unique in other ways (e.g., high frequency of medical comorbidities in 579 this population) and possibly distinct from other major biobanks; thus, it will be 580 necessary for other biobanks to also examine the genetics associated with TBI.

581

582 Conclusions

583 Learning more about the genetics associated with TBI risk and recovery is 584 necessary for developing a better understanding of the pathophysiology of this injury 585 and could aid in developing novel therapeutics. The results of this first large-scale 586 GWAS examining TBI in military Veterans identified 15 loci in the multi-ancestry cohort, 587 including genes previously known to be relevant to TBI biology that will be important to 588 investigate in future studies. Findings also showed that TBI is a heritable trait with 589 comparable genetic architecture and high genetic correlation with psychiatric and risk-590 taking traits. Results set the stage for future TBI GWAS studies within MVP that focus 591 on diversity and chronicity of symptom sequelae as well as severity of injury.

592

593

594

595 **References**

Helmick KM, Spells CA, Malik SZ, Davies CA, Marion DW, Hinds SR. Traumatic
 brain injury in the US military: Epidemiology and key clinical and research programs.
 Brain Imaging and Behavior. 2015;9(3):358-366.

599 2. DoD Numbers for Traumatic Brain Injury Worldwide - Totals (Defense Health 600 Agency) (2021).

Karr JE, Areshenkoff CN, Garcia-Barrera MA. The neuropsychological outcomes
 of concussion: a systematic review of meta-analyses on the cognitive sequelae of mild
 traumatic brain injury. *Neuropsychology*. 2014;28(3):321-336.

- 4. McCrea M, Guskiewicz K, Doncevic S, et al. Day of injury cognitive performance on the Military Acute Concussion Evaluation (MACE) by US military service members in OEF/OIF. *Military Medicine*. 2014;179(9):990-997.
- 5. Nelson LD, Temkin NR, Dikmen S, et al. Recovery after mild traumatic brain injury in patients presenting to US level I trauma centers: A transforming research and clinical knowledge in traumatic brain injury (TRACK-TBI) study. *JAMA Neurology*. 2019;76(9):1049-1059.
- 611 6. Chapman JC, Diaz-Arrastia R. Military traumatic brain injury: A review.
- 612 *Alzheimer's & Dementia*. 2014;10:S97-S104.
- 613 7. Schwab K, Terrio HP, Brenner LA, et al. Epidemiology and prognosis of mild
- 614 traumatic brain injury in returning soldiers: A cohort study. *Neurology*.
- 615 2017;88(16):1571-1579.
- 616 8. Perry DC, Sturm VE, Peterson MJ, et al. Traumatic brain injury is associated with 617 subsequent neurologic and psychiatric disease: A meta-analysis. *Journal of* 618 *Neurosurgery* 2016;124(2):511-526.
- 619 9. Stein MB, Ursano RJ, Campbell-Sills L, et al. Prognostic indicators of persistent 620 post-concussive symptoms after deployment-related mild traumatic brain injury: A
- 621 prospective longitudinal study in US Army soldiers. *Journal of Neurotrauma*.
- 622 2016;33(23):2125-2132.
- Stein MB, Jain S, Giacino JT, et al. Risk of posttraumatic stress disorder and
 major depression in civilian patients after mild traumatic brain injury: A TRACK-TBI
 study. *JAMA Psychiatry*. 2019;76(3):249-258.
- 626 11. Barnes DE, Byers AL, Gardner RC, Seal KH, Boscardin WJ, Yaffe K. Association 627 of mild traumatic brain injury with and without loss of consciousness with dementia in
- 628 US military veterans. *JAMA Neurology*. 2018;75(9):1055-1061.
- Brickell TA, Lange RT, French LM. Health-related quality of life within the first 5
 years following military-related concurrent mild traumatic brain injury and polytrauma. *Military Medicine*. 2014;179(8):827-838.
- 632 13. Sakamoto MS, Delano-Wood L, Schiehser DM, Merritt VC. Predicting veteran
- health-related quality of life following mild traumatic brain injury. *Rehabilitation Psychology*. 2021;doi:10.1037/rep0000392
- Agtarap SD, Campbell-Sills L, Jain S, et al. Satisfaction with life after mild
 traumatic brain injury: A TRACK-TBI study. *Journal of Neurotrauma*. 2021;38(5):546554.
- 15. Pietrzak RH, Johnson DC, Goldstein MB, Malley JC, Southwick SM.
- 639 Posttraumatic stress disorder mediates the relationship between mild traumatic brain
- 640 injury and health and psychosocial functioning in veterans of Operations Enduring

641 Freedom and Iragi Freedom. The Journal of nervous and mental disease.

642 2009;197(10):748-753.

643 MacDonald CL, Barber J, Jordan M, et al. Early clinical predictors of 5-year 16.

644 outcome after concussive blast traumatic brain injury. JAMA Neurology.

645 2017;74(7):821-829.

- 646 Taylor BC, Hagel EM, Carlson KF, et al. Prevalence and costs of co-occurring 17. 647 traumatic brain injury with and without psychiatric disturbance and pain among
- 648 Afghanistan and Iraq War Veteran VA users. Medical Care. 2012:342-346.
- 649 McAllister TW. Genetic factors modulating outcome after neurotrauma. PM&R. 18. 650 2010;2(12):S241-S252.
- 651 Jordan BD. Genetic influences on outcome following traumatic brain injury. 19. 652 Neurochemical Research. 2007;32(4):905-915.
- 653 Weaver SM, Chau A, Portelli JN, Grafman J. Genetic polymorphisms influence 20. 654 recovery from traumatic brain injury. The Neuroscientist. 2012;18(6):631-644.
- 655 Dardiotis E, Fountas KN, Dardioti M, et al. Genetic association studies in patients 21. 656 with traumatic brain injury. Neurosurgical Focus. 2010;28(1):E9.
- Zeiler FA, McFadyen C, Newcombe VF, et al. Genetic influences on patient-657 22.
- 658 oriented outcomes in traumatic brain injury: A living systematic review of non-
- 659 apolipoprotein E single-nucleotide polymorphisms. Journal of Neurotrauma.

660 2021;38(8):1107-1123.

- Panenka WJ, Gardner AJ, Dretsch MN, Crynen GC, Crawford FC, Iverson GL. 661 23. 662 Systematic review of genetic risk factors for sustaining a mild traumatic brain injury. 663 Journal of Neurotrauma. 2017;34(13):2093-2099.
- Lawrence DW, Comper P, Hutchison MG, Sharma B. The role of apolipoprotein 664 24. 665 E episilon (\Box)-4 allele on outcome following traumatic brain injury: A systematic review. 666 Brain Injury. 2015;29(9):1018-1031.
- Sun X-C, Jiang Y. Genetic susceptibility to traumatic brain injury and 667 25.
- apolipoprotein E gene. Chinese Journal of Traumatology. 2008;11(4):247-252. 668
- 669 Zhou W, Xu D, Peng X, Zhang Q, Jia J, Crutcher KA. Meta-analysis of APOE 4 26. allele and outcome after traumatic brain injury. Journal of Neurotrauma. 2008;25(4):279-670 671 290.
- 672 27. Zeng S, Jiang J-X, Xu M-H, et al. Prognostic value of apolipoprotein E epsilon4
- 673 allele in patients with traumatic brain injury: A meta-analysis and meta-regression.

674 Genetic Testing and Molecular Biomarkers. 2014:18(3):202-210.

- 675 McFadyen CA, Zeiler FA, Newcombe V, et al. Apolipoprotein E4 polymorphism 28. 676 and outcomes from traumatic brain injury: A living systematic review and meta-analysis. 677 Journal of Neurotrauma. 2021;38(8):1124-1136.
- 678 Gaziano JM, Concato J, Brophy M, et al. Million Veteran Program: A mega-29.
- 679 biobank to study genetic influences on health and disease. Journal of Clinical Epidemiology. 2016;70:214-223.
- 680
- 30. Schwab K, Ivins B, Cramer G, et al. Screening for traumatic brain injury in troops 681
- 682 returning from deployment in Afghanistan and Irag: initial investigation of the usefulness
- of a short screening tool for traumatic brain injury. The Journal of Head Trauma 683
- 684 Rehabilitation. 2007;22(6):377-389.

685 31. U.S. Department of Defense. Traumatic Brain Injury (TBI): DoD Standard 686 Surveillance Case Definition for TBI Adapted for AFHSD Use. U.S. Department of 687 Defense. 688 32. The 1000 Genomes Project Consortium. A global reference for human genetic 689 variation. Nature. 2015;526(7571):68-74. 690 Loh P-R, Danecek P, Palamara PF, et al. Reference-based phasing using the 33. 691 Haplotype Reference Consortium panel. Nature Genetics. 2016;48(11):1443-1448. 692 34. Fang H, Hui Q, Lynch J, et al. Harmonizing genetic ancestry and self-identified 693 race/ethnicity in genome-wide association studies. The American Journal of Human 694 Genetics. 2019;105(4):763-772. 695 Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen W-M. Robust 35. 696 relationship inference in genome-wide association studies. Bioinformatics. 697 2010:26(22):2867-2873. 698 Abraham G, Qiu Y, Inouye M. FlashPCA2: Principal component analysis of 36. 699 Biobank-scale genotype datasets. *Bioinformatics*. 2017;33(17):2776-2778. 700 Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-37. 701 generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience*. 702 2015;4(7) 703 38. Willer CJ, Li Y, Abecasis GR. METAL: Fast and efficient meta-analysis of 704 genomewide association scans. *Bioinformatics*. 2010;26(17):2190-2191. 705 Pruim RJ, Welch RP, Sanna S, et al. LocusZoom: Regional visualization of 39. 706 genome-wide association scan results. Bioinformatics. 2010;26(18):2336-2337. 707 40. Watanabe K, Taskesen E, Van Bochoven A, Posthuma D. Functional mapping 708 and annotation of genetic associations with FUMA. Nature Communications. 709 2017;8(1):1826. 710 41. Lee SH, Wray NR, Goddard ME, Visscher PM. Estimating missing heritability for 711 disease from genome-wide association studies. The American Journal of Human 712 Genetics. 2011;88(3):294-305. 713 42. Bulik-Sullivan BK, Loh P-R, Finucane HK, et al. LD Score regression 714 distinguishes confounding from polygenicity in genome-wide association studies. Nature 715 Genetics. 2015;47(3):291-295. 716 43. Holland D, Frei O, Desikan R, et al. Beyond SNP heritability: Polygenicity and discoverability of phenotypes estimated with a univariate Gaussian mixture model. 717 718 PLoS Genetics. 2020;16(5):e1008612. 719 Frei O, Holland D, Smeland OB, et al. Bivariate causal mixture model quantifies 44. 720 polygenic overlap between complex traits beyond genetic correlation. Nature 721 Communications. 2019;10:2417. 722 45. R Core Team. R: A language and environment for statistical computing. 723 https://www.R-project.org/ 724 Grotzinger AD. Rhemtulla M. de Vlaming R. et al. Genomic structural equation 46. 725 modelling provides insights into the multivariate genetic architecture of complex traits. 726 Nature Human Behaviour. 2019;3(5):513-525. 727 Watanabe Kea. A global view of genetic architecture in human complex traits. 47. 728 [under preparation].

- 48. Seripa D, D'Onofrio G, Panza F, Cascavilla L, Masullo C, Pilotto A. The genetics
- of the human APOE polymorphism. *Rejuvenation Research*. 2011;14(5):491-500.

731 49. Broman KW, Matsumoto N, Giglio S, et al. Common long human inversion 732 polymorphism on chromosome 8p. Lecture Notes-Monograph Series. 2003:237-245. 733 Schmid RS, Maness PF. Cell recognition molecules and disorders of 50. 734 neurodevelopment. International Handbook on Brain and Behaviour in Human 735 Development. Kluwer Academic Publishers; 2001:199-218. 736 Brennaman LH, Maness PF. NCAM in neuropsychiatric and neurodegenerative 51. 737 disorders. vol 663. Structure and Function of the Neural Cell Adhesion Molecule NCAM: 738 Advances in Experimental Medicine and Biology Springer; 2010:299-317. 739 Vukojevic V, Mastrandreas P, Arnold A, et al. Evolutionary conserved role of 52. 740 neural cell adhesion molecule-1 in memory. Translational Psychiatry. 2020;10:217. 741 Mahley RW, Huang Y. Apolipoprotein e sets the stage: Response to injury 53. 742 triggers neuropathology. Neuron. 2012;76(5):871-885. 743 Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: A causative factor and 54. 744 therapeutic target in neuropathology, including Alzheimer's disease. Proceedings of the 745 National Academy of Sciences. 2006;103(15):5644-5651. 746 Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the 55. 747 association between apolipoprotein E genotype and Alzheimer disease: A meta-748 analysis. JAMA. 1997;278(16):1349-1356. 749 Horsburgh K, McCarron MO, White F, Nicoll JA. The role of apolipoprotein E in 56. 750 Alzheimer's disease, acute brain injury and cerebrovascular disease: Evidence of 751 common mechanisms and utility of animal models. *Neurobiology of Aging*. 752 2000;21(2):245-255. 753 Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer's 57. 754 disease and other neurological disorders. The Lancet Neurology. 2011;10(3):241-252. 755 Reinvang I, Espeseth T, Westlye LT. APOE-related biomarker profiles in non-58. 756 pathological aging and early phases of Alzheimer's disease. Neuroscience & 757 Biobehavioral Reviews. 2013;37(8):1322-1335. 758 Van Giau V, Bagyinszky E, An SSA, Kim SY. Role of apolipoprotein E in 59. 759 neurodegenerative diseases. Neuropsychiatric Disease and Treatment. 2015;11:1723-760 1737. 761 60. Wisdom NM, Callahan JL, Hawkins KA. The effects of apolipoprotein E on non-762 impaired cognitive functioning: A meta-analysis. Neurobiology of Aging. 2011;32(1):63-763 74. 764 61. McAllister TW, Flashman LA, Harker Rhodes C, et al. Single nucleotide 765 polymorphisms in ANKK1 and the dopamine D2 receptor gene affect cognitive outcome 766 shortly after traumatic brain injury: A replication and extension study. Brain Injury. 767 2008;22(9):705-714. 768 Merritt VC, Clark AL, Sorg SF, et al. Apolipoprotein E ε 4 genotype is associated 62. 769 with elevated psychiatric distress in veterans with a history of mild to moderate 770 traumatic brain injury. Journal of Neurotrauma. 2018:35(19):2272-2282. 771 63. Merritt VC, Clark AL, Sorg SF, et al. Apolipoprotein E (APOE) £4 genotype is 772 associated with reduced neuropsychological performance in military veterans with a 773 history of mild traumatic brain injury. Journal of Clinical and Experimental 774 Neuropsychology. 2018;40(10):1050-1061.

775 64. Merritt VC, Lange RT, Lippa SM, et al. Apolipoprotein e (APOE) ε4 genotype

influences memory performance following remote traumatic brain injury in US military
 service members and veterans. *Brain and cognition*. 2021;154:105790.

65. Zhao X, Yang Y, Sun B-F, Zhao Y-L, Yang Y-G. FTO and obesity: Mechanisms of association. *Current Diabetes Reports*. 2014;14(5):1-9.

66. McCarthy MI. Genomics, type 2 diabetes, and obesity. *New England Journal of Medicine*. 2010;363(24):2339-2350.

782 67. Reitz C, Tosto G, Mayeux R, Luchsinger JA, Group N-LNFS, Initiative tAsDN.

Genetic variants in the Fat and Obesity Associated (FTO) gene and risk of Alzheimer's
 disease. *PloS One*. 2012;7(12):e50354.

68. Li H, Ren Y, Mao K, et al. FTO is involved in Alzheimer's disease by targeting
TSC1-mTOR-Tau signaling. *Biochemical and Biophysical Research Communications*.
2018;498(1):234-239.

69. Co M, Anderson AG, Konopka G. FOXP transcription factors in vertebrate brain

development, function, and disorders. Wiley Interdisciplinary Reviews: Developmental
 Biology. 2020;9(5):e375.

791 **70.** Den Hoed J, Devaraju K, Fisher SE. Molecular networks of the FOXP2 792 transcription factor in the brain. *EMBO Reports*. 2021;22(8):e52803.

793 71. Stein MB, Levey DF, Cheng Z, et al. Genome-wide association analyses of post-

traumatic stress disorder and its symptom subdomains in the Million Veteran Program.
 Nature Genetics. 2021;53(2):174-184.

72. Linnér RK, Biroli P, Kong E, et al. Genome-wide association analyses of risk
tolerance and risky behaviors in over 1 million individuals identify hundreds of loci and
shared genetic influences. *Nature Genetics*. 2019;51(2):245-257.

799 73. Bush G, Luu P, Posner MI. Cognitive and emotional influences in anterior 800 cingulate cortex. *Trends in Cognitive Sciences*. 2000;4(6):215-222.

801 74. Stevens FL, Hurley RA, Taber KH. Anterior cingulate cortex: unique role in
802 cognition and emotion. *The Journal of Neuropsychiatry and Clinical Neurosciences*.
803 2011;23(2):121-125.

Kunkle BW, Grenier-Boley B, Sims R, et al. Genetic meta-analysis of diagnosed
 Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid
 processing. *Nature Genetics*. 2019;51(3):414-430.

807

808

809 810

811

812

813

814

815

816 817

818

819

820

821 Acknowledgements

The authors sincerely thank the Veterans who volunteered to participate in the Million Veteran Program. This research is based on data from the Million Veteran Program (Project MVP026), Office of Research and Development, Veterans Health Administration. This publication does not represent the views of the Department of Veteran Affairs or the United States Government.

827

828 Funding

This work was supported by a Career Development Award awarded to Dr. Merritt from the VA Clinical Science Research & Development Service (IK2 CX001952).

831

832 Author Contributions

833 Overall study coordination: VCM, CMN. Study concept and design: VCM, CMN,

AXM, LDW. Data curation: CCC. Phenotype analysis: CCC (lead), VCM, LDW.

835 Statistical analysis: AXM (lead), MG, EK. Data interpretation: AXM, MG, CMN, MBS,

MSP, RLH, MWL, VCM. Writing: VCM (lead), AXM, CMN. All authors provided edits,

feedback, and approved the final version of the paper for submission.

838

839 Conflicts of Interest

- 840 The authors have no conflicts of interest to declare.
- 841

842 Figure Legends

843

Figure 1. Manhattan plot of TBI risk for the **multi-ancestry cohort**. The GWAS was conducted using logistic regression, including first 10 principal components of ancestry as covariates. The x-axis displays the chromosome position, and the y-axis shows the GWAS *p* value on a -log₁₀ scale. The red dashed line reflects genome-wide significance at

849 $p < 5 \times 10^{-8}$

850

Figure 2a. Gene tissue expression (tissues aggregated) in the multi-ancestry cohort.
Figure 2b. Gene tissue expression (stratified by tissue subtype) in the multi-ancestry
cohort.

854

Figure 3. Genetic correlation between TBI and other phenotypes.

The x-axis denotes the magnitude of genetic correlation. The blue squares represent

the genetic correlation between TBI and each given phenotype, with lines representing

- 858 95% confidence intervals.
- 859

Figure 4. Genomic structural equation modeling (gSEM) results. Correlated factors

861 model with standardized estimates and standard error estimates in parentheses.

862 Genetic components of disorders are in circles and latent factors are represented by

ovals. Single-headed arrows represent regression relationships and parameter

864 estimates that can be squared to estimate the proportion of variance accounted for by

components. Double-headed arrows represent correlations. Residual variance
 represented by double-headed arrow connecting the variable to itself. Each phenotype

loads onto at least one factor. The TBI risk variable is loaded onto its own factor (T_q)

while the psychiatric disorders loaded onto one factor $(F1_q)$ and the risk-taking

behaviors loaded onto another factor ($F2_g$); CFI=0.908. <u>Abbreviations</u>: TBI = traumatic

brain injury; MDD = major depressive disorder; NEUR = neuroticism; PTSD =

871 posttraumatic stress disorder; ALCH = alcohol dependence; GRT = general risk

tolerance; ADHD = attention-deficit/hyperactivity disorder.

873

874 Figure 5. Multiple regression results. Genetic components of disorders are in circles. Single-headed arrows represent regression relationships and parameter estimates that 875 876 can be squared to estimate the proportion of variance accounted for. Double-headed 877 arrows represent correlations. Residual variance represented by double-headed arrow 878 connecting the variable to itself. The models reflect the genetic association between TBI 879 and (A) PTSD, (B) alcohol dependence, and (C) ADHD while controlling for general risk 880 taking. *Abbreviations*: PTSD = posttraumatic stress disorder; GRT = general risk 881 tolerance; TBI = traumatic brain injury; ALCH = alcohol dependence; ADHD = attention-882 deficit/hyperactivity disorder. 883

884



Figure 1

medRxiv preprint doi: https://doi.org/10.1101/2023.02.16.23286045; this version posted February 17, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.









Figure 3











	Overall	TBI Case	Control	n
	N=304,485	n=111,494	n=192,991	μ
Age, Mean (SD)	64.36 (13.16)	59.92 (14.55)	66.92 (11.54)	<.001
Sex, N (%)				
Male	281,108 (92.3)	103,378 (92.7)	177,730 (92.1)	< 001
Female	23,370 (7.7)	8,109 (7.3)	15,261 (7.9)	<.001
Missing	7 (0.0)	7 (0.0)	0 (0.0)	
Ancestry, N (%)				
European	249,785 (82.0)	85,613 (76.8)	164,172 (85.1)	< 001
African	35,470 (11.6)	15,714 (14.1)	19,756 (10.2)	<.001
Hispanic	19,230 (6.3)	10,167 (9.1)	9,063 (4.7)	
Data Source, N (%)				
BL	9,039 (3.0)	9,039 (8.1)		
LS	4,101 (1.3)	4,101 (3.7)		
ICD	23,776 (7.8)	23,776 (21.3)		
BL + LS	45,270 (14.8)	44,544 (40.0)		
BL + ICD	11,557 (3.8)	11,557 (10.4)		
LS + ICD	2,558 (0.8)	2,558 (2.3)		
BL + LS + ICD	208,184 (68.4)	15,919 (14.3)		
TBI Source, N (%)				
BL-CC	6,623 (2.2)	6,623 (5.9)		
BL-TBI	1,251 (0.4)	1,251 (1.1)		
LS	4,101 (1.3)	4,101 (3.7)		
ICD	58,606 (19.2)	57,880 (51.9)		
BL-CC + BL-TBI	1,165 (0.4)	1,165 (1.0)		
BL-CC + LS	13,982 (4.6)	13,982 (12.5)		
BL-CC + ICD	1,399 (0.5)	1,399 (1.3)		
BL-TBI + ICD	3,138 (1.0)	3,138 (2.8)		
LS + ICD	205,154 (67.4)	12,889 (11.6)		
BL-CC + BL-TBI + ICD	3,478 (1.1)	3,478 (3.1)		
BL-CC + LS + ICD	2,106 (0.7)	2,106 (1.9)		
BL-TBI + LS + ICD	1,419 (0.5)	1,419 (1.3)		
All 4 Sources	2,063 (0.7)	2,063 (1.9)		

Abbreviations: BL = MVP Baseline Survey; LS = MVP Lifestyle Survey; ICD = International Statistical Classification of Diseases; BL-CC = MVP Baseline Survey, Concussion or Loss of Consciousness; BL-TBI = MVP Baseline Survey, Traumatic Brain Injury

Table 2. Genome-wide significant loci associated with TBI (case-control) for multi-ancestry, EA, AA, and HA cohorts.

						j.	Multi-Ancestry (111,494 cases, 192,991 controls) European Ancestry (85,613 cases, 164,172 controls)						African A	cestry (15,714	Hispanic An	cestry (10,1	67 cases, 9,0	63 controls	al				
Locus	SNP	Chr	Start	Stop	A1	A2	A1 Freq	Z-score	p -value	HetPVal	A1 Freq	OR	SE	p-value	A1 Freq	OR	SE	p-value	A1 Freq	OR	SE	p -value	Genes
1	rs140930533*	1	73,766,431	73,991,651	CAG	C	0.570	-0.035	1.49E-09	0.680	0.573	0.968	0.006	4.09E-07	0.641	0.956	0.017	0.007	0.406	0.955	0.022	0.037	ZRANB2, LRRC53, LHXB
2	rs623111^	1	190,886,930	191,418,368	Α	C	0.404	0.034	3.33E-09	0.242	0.373	1.038	0.006	1.78E-09	0.670	1.008	0.017	0.649	0.340	1.027	0.022	0.235	BRINP3, RGS21
2	rs11332270*	1	191,154,894	191,418,368	G	GA	0.403	0.034	3.16E-09	0.309	0.372	1.038	0.006	2.28E-09	0.671	1.010	0.017	0.548	0.339	1.026	0.022	0.246	RG521
3	rs4557006^	2	22,430,795	22,493,637	Α	G	0.441	0.028	5.96E-07	0.063	0.442	1.034	0.006	4.87E-08	0.342	1.009	0.016	0.568	0.611	0.986	0.023	0.542	NA
4	rs138580110*	2	78,623,429	78,838,751	Α	ATTAT	0.316	-0.036	4.33E-09	0.751	0.333	0.966	0.006	1.04E-07	0.122	0.948	0.024	0.027	0.277	0.968	0.024	0.170	NA
5	rs34799259^	2	144,151,161	144,248,905	Α	AT	0.579	-0.030	1.35E-07	0.191	0.565	0.966	0.006	2.95E-08	0.612	0.995	0.017	0.753	0.717	0.988	0.024	0.611	ARHGAP15, GTDC1, ZEB2
6	rs17394072^	2	222,869,560	222,872,562	Α	G	0.507	-0.031	4.05E-08	0.078	0.476	0.965	0.006	2.95E-09	0.819	1.002	0.020	0.928	0.547	0.997	0.021	0.903	FAM124B
6	rs562684959*	2	222,869,560	222,921,656	CT	с	0.535	-0.032	3.54E-08	0.770	0.512	0.970	0.006	8.60E-07	0.668	0.959	0.017	0.017	0.608	0.978	0.023	0.324	PAX3, CCDC140, SGPP2, FAM124B
7	rs4377571^	4	154,650,106	154,768,011	Α	т	0.454	0.032	1.89E-08	0.073	0.464	1.037	0.006	7.22E-09	0.411	0.996	0.017	0.821	0.403	1.040	0.022	0.069	TMEM154, TIGD4, ARFIP1, FHDC1, MND1, TLR2, RNF175, SFRP2, PLRG1, FGA
7	rs566208700*	4	154,650,106	154,768,011	G	GGTGTGTGTGTGT	0.564	-0.033	7.64E-09	0.193	0.539	0.966	0.006	1.58E-08	0.738	0.998	0.019	0.913	0.642	0.952	0.023	0.030	TMEM154, TIGD4, ARFIP1, FHDC1, MND1, TLR2, RNF175, SFRP2, PLRG1, FGA
8	rs147355048^	5	107,402,938	107,597,787	А	AGGATGGGATG	0.555	-0.030	1.51E-07	0.144	0.529	0.967	0.006	4.57E-08	0.825	0.975	0.022	0.253	0.620	1.011	0.022	0.617	EFNA5, FBXL17, MAN2A1, TMEM232, SLC25A46
9	rs12705715^	7	110,267,021	110,284,071	Α	G	0.490	-0.028	7.19E-07	0.057	0.466	0.967	0.006	3.87E-08	0.786	1.004	0.020	0.851	0.430	1.005	0.022	0.826	LRRN3, TMEM168
10	rs71149745*^	7	113,858,363	114,290,415	Α	AAATTTCAT	0.597	0.038	5.46E-11	0.848	0.576	1.040	0.006	3.28E-10	0.839	1.028	0.022	0.207	0.613	1.034	0.022	0.134	PPP1R3A, FOXP2, MDFIC
11	rs201720501*	7	114,940,147	115,113,279	т	TG	0.561	0.034	1.02E-08	0.812	0.538	1.034	0.006	2.91E-07	0.744	1.031	0.019	0.114	0.575	1.049	0.023	0.036	WNT2
12	rs34350548^	10	94,577,629	94,750,745	т	TA	0.362	-0.038	1.96E-09	0.179	0.380	0.958	0.007	4.31E-10	0.204	0.999	0.023	0.978	0.275	0.981	0.028	0.487	KIF11, EXOC6, CYP26C1, CYP26A1, MYOF, CEP55, LGI1
12	rs4933752*	10	94,570,602	94,756,363	т	c	0.307	-0.039	6.00E-10	0.937	0.323	0.962	0.007	3.33E-09	0.084	0.954	0.032	0.141	0.191	0.969	0.028	0.252	KIF11, EXOC6, CYP26C1, CYP26A1, MYOF, CEP55, LG/1
13	rs1940701*^	11	112,826,311	113,048,466	т	с	0.595	-0.040	4.38E-13	0.303	0.601	0.961	0.006	1.32E-10	0.609	0.973	0.016	0.078	0.506	0.934	0.021	0.001	IL18, TEX12, AP002884.3, BCO2, NCAM1, TMPRSS5
14	rs12891288*	14	103,849,715	104,053,764	т	с	0.277	0.035	4.29E-08	0.758	0.275	1.036	0.007	4.65E-07	0.277	1.039	0.018	0.032	0.306	1.018	0.024	0.452	ANKRD9, TNFAIP2, EIF5, MARK3, CKB, TRMT61A, BAG5, KLC1, RP11-73M18.2, APOPT1, XRCC3, AL049840.1, ZFYVE21, PPP1R13B, C14or/2, TDRD9, KIF26A
15	rs9972653^	16	53,797,908	53,845,487	т	G	0.395	-0.030	4.54E-08	0.284	0.398	0.966	0.006	2.31E-08	0.418	0.991	0.015	0.567	0.289	0.979	0.023	0.350	RPGRIP1L, FTO, RP11-324D17.1, IRX3, IRX5, IRX6, IMMP2, CES1, GNA01, MT1B, MT1F, MT1G, MT1H, MT1X
15	rs62033400*	16	53,797,908	53,845,487	А	G	0.628	0.033	1.02E-08	0.858	0.604	1.035	0.006	2.37E-08	0.897	1.026	0.025	0.317	0.744	1.024	0.024	0.333	RPGRIP1L, FTO, RP11-324D17.1, IRX3, IRX5, IRX6, IMMP2, CES1, GNA01, MT1B, MT1F, MT1G, MT1H, MT1X
16	rs79940062^	17	4,708,126	4,879,323	А	G	NA	NA	NA	NA	0.023	1.129	0.020	9.11E-10	NA	NA	NA	NA	NA	NA	NA	NA	UBE2G1, MED11, VMO1, GLTPD2, PSMB6, PLD2, MINK1, CHRNE, C17or/107, SLC25A11, RNF167, PFN1, ENO3, SPAG7, CAMTA2, INCA1, KIF1C, SCIMP, NLRP1
17	rs4608411^	18	52,765,283	52,827,668	т	с	0.322	0.041	2.70E-11	0.210	0.334	1.041	0.007	8.44E-10	0.111	1.010	0.026	0.688	0.343	1.073	0.023	0.002	RAB27B, TCF4, TXNL1, WDR7, NARS, NEDD4L
17	rs729053*	18	52,765,283	52,827,668	с	G	0.324	0.040	1.32E-11	0.302	0.335	1.040	0.006	1.04E-09	0.097	1.022	0.027	0.412	0.342	1.073	0.022	0.001	RAB27B, TCF4, TXNL1, WDR7, NAR5, NEDD4L
18	rs618869^	18	53,198,836	53,456,801	т	C	NA	NA	NA	NA	0.145	0.951	0.009	3.50E-08	NA	NA	NA	NA	0.080	0.970	0.043	0.484	STARD6, C18orf54
18	rs651350*	18	53,210,302	53,464,917	А	G	0.876	0.049	2.14E-08	0.825	0.871	1.051	0.009	5.29E-08	0.975	1.071	0.052	0.186	0.938	1.028	0.044	0.529	STARD6, C18or/54
19	rs429358*^	19	45,392,254	45,424,351	т	C	0.851	-0.051	2.60E-11	0.335	0.862	0.949	0.009	1.08E-09	0.787	0.945	0.018	0.002	0.890	0.996	0.033	0.905	PVRL2, TOMM40, APOE, APOC1, APOC4-APOC2, APOC4, APOC2, CTB-129P6.11, CLPTM1, CLASRP, TRAPPC6A, BLOC1S3, AC005779.2
20	rs148108087*	19	51,781,455	51,815,081	А	G	0.053	-0.079	2.50E-08	0.857	0.055	0.925	0.015	1.13E-07	0.010	0.907	0.086	0.259	0.019	0.884	0.088	0.161	NAPSA, C19or/148, SIGLECL1, IGLON5, VSIG10I, ETFB, CTD-2616J11.11, CLDND2, NKG7, ZNF577
											•				•								

Note: For multi-ancestry analysis, a SNP had to be present in all 3 ancestries (EA, AA, and HA) There were no independently significant hits in the African or Hispanic ancestries. "Yog SNP (within each locus) in the European ancestry cohort.

				Multi-Ancesti	ry			European And			
SYMBOL	CHR	START	STOP	NSNPS	NPARAM	ZSTAT	Р	NSNPS	NPARAM	ZSTAT	Р
SFRP2*^	4	154701744	154710272	16	4	4.761	9.65E-07	18	5	4.579	2.34E-06
RNF175*^	4	154631277	154681387	208	12	4.951	3.70E-07	216	13	5.040	2.33E-07
TSSK1B^	5	112768251	112770728	-		-	-	15	4	4.605	2.06E-06
FBXL17^	5	107194736	107717799	-		-	-	1390	38	4.703	1.28E-06
FOXP2*^	7	113726382	114333827	889	34	5.439	2.68E-08	1122	49	5.794	3.43E-09
MSRA*	8	9911778	10286401	1471	59	4.707	1.25E-06	-		-	
FAM120A*^	9	96214004	96328397	300	15	4.704	1.28E-06	354	19	5.054	2.17E-07
PHF2^	9	96338689	96441869	-		-	-	491	26	5.270	6.84E-08
EXOC6*^	10	94590935	94819250	525	19	4.775	8.97E-07	652	26	4.663	1.56E-06
NCAM1*^	11	112831997	113149158	848	38	6.835	4.10E-12	999	57	6.195	2.92E-10
NAV3*^	12	78224685	78606790	1251	63	5.152	1.29E-07	1463	78	5.097	1.73E-07
TRMT61A*	14	103995521	104003410	18	3	4.488	3.59E-06	-		-	
RCN2^	15	77223960	77242601	-		-	-	34	12	4.499	3.42E-06
TCF12^	15	57210821	57591479	-		-	-	1009	18	4.515	3.16E-06
FTO*^	16	53737875	54155853	1303	93	5.675	6.94E-09	1503	116	5.617	9.72E-09
RBFOX1*	16	6069095	7763340	9543	385	4.937	3.98E-07	-		-	
AKAP10^	17	19807615	19881656	-		-	-	123	8	4.674	1.48E-06
DCC*^	18	49866542	51057784	4415	85	4.993	2.97E-07	5169	101	4.926	4.19E-07
APOE*^	19	45409011	45412650	5	2	5.955	1.30E-09	6	3	5.682	6.66E-09
APOC1*	19	45417504	45422606	11	3	4.621	1.91E-06	-		-	
FAM46D^	Х	79591003	79700810	-		-	-	58	3	5.055	2.15E-07
BRWD3^	Х	79926353	80065187	-		-	-	180	10	4.540	2.81E-06

Table 3. Gene-based loci analysis (Bonferroni significant) in the multi-ancestry and European ancestry cohorts.

Notes: N=304,485 for the multi-ancestry cohort; N=249,785 for the European ancestry cohort.

*top gene in the multi-ancestry cohort.

^top gene in the European ancestry cohort.